Using matched pancreatic ductal organoids and pancreatic cancer organoids the lack of therapeutic response of dual MEK-AKT inhibition observed in a clinical phase II trial (69) was investigated. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.